DCO
The Digital Cooperation Organization (DCO), a global multilateral organization committed to enabling digital prosperity for all by accelerating the sustainable and inclusive growth of the digital economy, hosted a strategic roundtable discussion with major technology companies, and social media and digital platform representatives to address the societal impact of the spread of online misinformation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240828374432/en/
Representatives from social media, technology companies, and digital platforms at the DCO HQ (Photo AETOSWire)
Building on the series of global roundtables conducted in 2023 as part of the “combating online misinformation” Digital Space Accelerators, this roundtable continuous the DCO’s ongoing efforts to combat online misinformation. Representatives from Google, LinkedIn, Meta and TikTok participated as key stakeholders to discuss this crucial issue affecting the digital world.
The roundtable, held at the DCO headquarters in Riyadh, Saudi Arabia, aimed to identify challenges and propose innovative solutions to foster trust and safeguard the digital economy. The participation of representatives from social media and digital platforms underscored the importance of the roundtable, providing a crucial platform for stakeholders to exchange perspectives and explore collaborative actions to combat online misinformation.
The discussions aimed to create an ongoing dialogue on the gravity of online misinformation as both a societal problem and a challenge to the digital economy. It also provided a platform for stakeholders to bridge their perspectives and work together to combat online misinformation, thereby ensuring a trustworthy digital information ecosystem.
"The exchange of ideas and insights from leading platforms has been invaluable. The key takeaway from the discussion was the importance of cooperation through a multistakeholder approach to combat online misinformation, which aligns with the DCO’s mission. We are confident that the outcomes of this roundtable will pave the way for a more informed and resilient digital society, and we look forward to our next collaborative roundtable to enable digital prosperity for all", said Alaa Abdulaal, Chief of the Digital Economy Foresight department at the Digital Cooperation Organization.
Sarah Al-Husseini, Head of Government Affairs & Public Policy, KSA at Google, said: “People come to Google because they trust they will be able to find high quality information, which is why we take our commitment to combating misinformation through our products and our content policies very seriously. We work hard to retain that trust - designing our systems for quality and ensuring users are given access to a range of information from different voices and the tools to know what they can trust. We do not do it alone; in addition to continuously adapting our policies and technologies to prevent abuse, we openly share our technology and collaborate with experts to drive the industry forward and create a safer internet for everyone.”
Ranim Alamin, Strategic Government Partnerships Head, KSA at LinkedIn, said: “Taking part in the DCO's strategic roundtable offered us a valuable opportunity to discuss one of the more pressing issues in the digital world: Misinformation. The conversations we had with representatives from various leading platforms underscored the importance of a united approach to foster trust. We are committed to working together to build a more trusted and resilient digital information ecosystem.”
Tom Bonsundy-O'Bryan, Misinformation Policy, EMEA Lead at Meta, said: “We were glad to attend this roundtable organized by the DCO and remain deeply committed to tackling misinformation - balancing our values of expression, safety, authenticity and privacy.”
Hatem Samman, Executive Director of Government Relations & Public Policy, KSA at TikTok, said: “At TikTok, we are committed to fostering a secure and trustworthy digital environment for the community. This roundtable provided an essential platform for discussing innovative strategies and collaborative actions to combat misinformation. By working together, we can create a safe, authentic space where people can discover content that is original and engage with people who are authentic.”
The Digital Cooperation Organization remains committed to fostering a collaborative approach to combating misinformation and ensuring the growth of the digital economy. The DCO looks forward to continuing this impactful work with its partners in the social media and digital platform space.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828374432/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
